RecruitingPosttraumatic HeadacheMild Traumatic Brain Injury
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
Eligible age
18–50 yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).
Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
You may qualify if…
- ✓ Male or female ≥18 and ≤50 years of age
- ✓ mTBI from any cause including impact, rotational acceleration, blast, or a combination, has occurred within the prior 7 days
- ✓ PTH has occurred within the prior 7 days
- ✓ Able to provide informed consent
- ✓ Likely to stay in the same geographical area for the duration of study
- ✓ Has a personal health care provider for standard of care PTH and TBI, including education, diagnostic procedures including neuroimaging and treatment, as deemed clinically indicated by the health care provider
You may not qualify if…
- ✕ Sustained a moderate or severe TBI, rather than mTBI, indicated with at least 1 of the following associated with head injury:
- ✕ 1. abnormal structural imaging
- ✕ 2. loss of consciousness for \>30 minutes
- ✕ 3. alteration of consciousness/mental state for \>24 hours 3. post-traumatic amnesia for \>1 day
- ✕ Participants with ongoing chronic migraine or other chronic daily headache disorders at the time of injury
Where it's recruiting
Source: ClinicalTrials.gov · NCT05049057 · last updated 2024-02-22